Compare Citius Pharmaceuticals Inc (CTXR) vs First Solar, Inc. (FSLR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs First Solar, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while First Solar, Inc. trades at $177.82 (market cap $19.22B). The key difference: First Solar, Inc. is far larger — about 1411.2× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 2,067,793). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and First Solar, Inc. for 76 Days on average.
| CTXR | FSLR | |
|---|---|---|
Market Cap | $13.62M | $19.22B |
Volume | 132,438 | 2,067,793 |
Sector | Health | Energy |
52-Week High | $1.82 | $318.30 |
52-Week Low | $0.48 | $172.11 |
Typical Hold Time | 17 Days | 76 Days |
Enterprise Value | $3.79M | $17.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
First Solar (FSLR) trades at $177.82, down 1.28% on the day, amid a bearish technical signal and recent sector-wide pressures. The stock shows strong fundamentals with a P/E of 11.03, net income margin of 32.47%, and robust cash flow from operations of $2.06B in 2025. Recent news includes a patent infringement lawsuit filed on October 1, 2026, which briefly lifted the stock, while high put option volume on October 3, 2026, indicates investor caution.
FSLR presents a mixed outlook: solid profitability and analyst consensus support a 'Moderate Buy' with a $267.59 price target, but technical weakness and solar sector headwinds from high borrowing costs pose near-term risks. The stock's 44.9% decline from its all-time high highlights volatility, yet earnings beats in Q1 and Q2 2026 underscore operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →
